• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

危重症脓毒性休克患者血浆 EphA2 受体水平的临床意义。

Clinical implications of the plasma EphA2 receptor level in critically ill patients with septic shock.

机构信息

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ewha Medical Research Institute, Ewha Womans University School of Medicine, Seoul, Republic of Korea.

Yonsei University College of Medicine, Seoul, Republic of Korea.

出版信息

Sci Rep. 2017 Dec 14;7(1):17612. doi: 10.1038/s41598-017-17909-7.

DOI:10.1038/s41598-017-17909-7
PMID:29242524
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5730544/
Abstract

The Eph/ephrin receptor ligand system is known to play a role in inflammation induced by infection, injury, and inflammatory diseases. The present study aimed to evaluate plasma EphA2 receptor levels in critically ill patients with sepsis. This study was a prospective cohort study evaluating samples and clinical data from the medical intensive care unit (MICU) of a 2000-bed university tertiary referral hospital in South Korea. Positive correlations of the plasma EphA2 receptor level with the acute physiology and chronic health evaluation (APACHE) II score and the sequential organ failure assessment (SOFA) score were observed. The area under the curve (AUC) for the plasma EphA2 receptor level on a receiver operating characteristic curve was 0.690 (95% confidence interval [CI], 0.608-0.764); the AUCs for the APACHE II score and SOFA scores were 0.659 (95% CI, 0.576-0.736) and 0.745 (95% CI, 0.666-0.814), respectively. A Cox proportional hazard model identified an association between an increased plasma EphA2 receptor level (>51.5 pg mL) and increased risk of 28-day mortality in the MICU (hazard ratio = 3.22, 95% CI, 1.709-6.049). An increased plasma EphA2 receptor level was associated with sepsis severity and 28-day mortality among sepsis patients.

摘要

Eph/ephrin 受体配体系统已知在感染、损伤和炎症性疾病引起的炎症中发挥作用。本研究旨在评估脓毒症重症患者的血浆 EphA2 受体水平。本研究是一项前瞻性队列研究,评估了来自韩国一家 2000 张床位的大学三级转诊医院的内科重症监护病房(MICU)的样本和临床数据。观察到血浆 EphA2 受体水平与急性生理学和慢性健康评估 (APACHE) II 评分和序贯器官衰竭评估 (SOFA) 评分呈正相关。受试者工作特征曲线下的血浆 EphA2 受体水平曲线下面积为 0.690(95%置信区间 [CI],0.608-0.764);APACHE II 评分和 SOFA 评分的 AUC 分别为 0.659(95%CI,0.576-0.736)和 0.745(95%CI,0.666-0.814)。Cox 比例风险模型确定,血浆 EphA2 受体水平升高(>51.5pg/mL)与 MICU 28 天死亡率升高相关(风险比=3.22,95%CI,1.709-6.049)。在脓毒症患者中,血浆 EphA2 受体水平升高与脓毒症严重程度和 28 天死亡率相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0a/5730544/338e25f06196/41598_2017_17909_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0a/5730544/68f55a7ddbc5/41598_2017_17909_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0a/5730544/656431f55904/41598_2017_17909_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0a/5730544/a6f5df9470ce/41598_2017_17909_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0a/5730544/338e25f06196/41598_2017_17909_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0a/5730544/68f55a7ddbc5/41598_2017_17909_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0a/5730544/656431f55904/41598_2017_17909_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0a/5730544/a6f5df9470ce/41598_2017_17909_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0a/5730544/338e25f06196/41598_2017_17909_Fig4_HTML.jpg

相似文献

1
Clinical implications of the plasma EphA2 receptor level in critically ill patients with septic shock.危重症脓毒性休克患者血浆 EphA2 受体水平的临床意义。
Sci Rep. 2017 Dec 14;7(1):17612. doi: 10.1038/s41598-017-17909-7.
2
[Lactic acid, lactate clearance and procalcitonin in assessing the severity and predicting prognosis in sepsis].[乳酸、乳酸清除率及降钙素原在评估脓毒症严重程度及预测预后中的作用]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Apr;32(4):449-453. doi: 10.3760/cma.j.cn121430-20200129-00086.
3
[The prognostic value of serum procalcitonin on severity of illness in non-sepsis critically ill patients].[血清降钙素原对非脓毒症危重症患者病情严重程度的预后价值]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2016 Aug;28(8):688-93. doi: 10.3760/cma.j.issn.2095-4352.2016.08.004.
4
[Combined prognostic value of serum lactic acid, procalcitonin and severity score for short-term prognosis of septic shock patients].[血清乳酸、降钙素原及严重程度评分对脓毒症休克患者短期预后的联合预测价值]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Mar;33(3):281-285. doi: 10.3760/cma.j.cn121430-20201113-00715.
5
Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: relation to disease severity, multiple organ dysfunction, and mortality.危重病(包括脓毒症和脓毒性休克)患者血浆粒细胞集落刺激因子和粒细胞巨噬细胞集落刺激因子水平:与疾病严重程度、多器官功能障碍及死亡率的关系
Crit Care Med. 2000 Jul;28(7):2344-54. doi: 10.1097/00003246-200007000-00028.
6
Combining sequential organ failure assessment (SOFA) score with acute physiology and chronic health evaluation (APACHE) II score to predict hospital mortality of critically ill patients.将序贯器官衰竭评估(SOFA)评分与急性生理与慢性健康状况评估(APACHE)II评分相结合,以预测危重症患者的医院死亡率。
Anaesth Intensive Care. 2007 Aug;35(4):515-21. doi: 10.1177/0310057X0703500409.
7
[Combination of Weighted index of comorbidities and sepsis-related organ failure assessment score in death risk evaluation of septic patients].[合并症加权指数与脓毒症相关器官功能衰竭评估评分相结合在脓毒症患者死亡风险评估中的应用]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014 Jan;26(1):41-5.
8
Adaptation and Validation of a Pediatric Sequential Organ Failure Assessment Score and Evaluation of the Sepsis-3 Definitions in Critically Ill Children.儿童序贯器官衰竭评估评分的适应性与验证及危重症儿童中脓毒症-3定义的评估
JAMA Pediatr. 2017 Oct 2;171(10):e172352. doi: 10.1001/jamapediatrics.2017.2352.
9
Sequential Organ Failure Assessment predicts outcomes of pulse indicator contour continuous cardiac output-directed goal therapy: A prospective study.序贯器官衰竭评估可预测脉搏指示连续心输出量导向目标治疗的结果:一项前瞻性研究。
Medicine (Baltimore). 2017 Sep;96(39):e8111. doi: 10.1097/MD.0000000000008111.
10
The ratio of plasma angiopoietin-2 to angiopoietin-1 as a prognostic biomarker in patients with sepsis.脓毒症患者血浆血管生成素-2 与血管生成素-1 比值作为预后生物标志物。
Cytokine. 2020 May;129:155029. doi: 10.1016/j.cyto.2020.155029. Epub 2020 Feb 12.

引用本文的文献

1
Plasma EphA2 level is a superior biomarker to Del-1 for sepsis diagnosis and prognosis.血浆EphA2水平是比Del-1更优的脓毒症诊断和预后生物标志物。
Front Med (Lausanne). 2025 Jan 24;12:1505882. doi: 10.3389/fmed.2025.1505882. eCollection 2025.
2
NADPH oxidase 4 signaling in a ventilator-induced lung injury mouse model.NADPH 氧化酶 4 信号在呼吸机诱导肺损伤小鼠模型中的作用。
Respir Res. 2022 Mar 27;23(1):73. doi: 10.1186/s12931-022-01992-0.
3
Biological correlates before esophageal cancer screening and after diagnosis.食管癌筛查前和诊断后的生物学相关因素。

本文引用的文献

1
Inhibition of EphA2/EphrinA1 signal attenuates lipopolysaccharide-induced lung injury.抑制EphA2/EphrinA1信号可减轻脂多糖诱导的肺损伤。
Clin Sci (Lond). 2016 Nov 1;130(21):1993-2003. doi: 10.1042/CS20160360. Epub 2016 Aug 22.
2
Sepsis-induced elevation in plasma serotonin facilitates endothelial hyperpermeability.脓毒症诱导的血浆血清素升高会促进内皮细胞高通透性。
Sci Rep. 2016 Mar 9;6:22747. doi: 10.1038/srep22747.
3
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).《脓毒症及脓毒性休克第三次国际共识定义(脓毒症-3)》
Sci Rep. 2021 Aug 23;11(1):17015. doi: 10.1038/s41598-021-96548-5.
JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.
4
Deaths: Leading Causes for 2011.死亡:2011年的主要死因。
Natl Vital Stat Rep. 2015 Jul 27;64(7):1-96.
5
Sepsis: a roadmap for future research.脓毒症:未来研究的路线图。
Lancet Infect Dis. 2015 May;15(5):581-614. doi: 10.1016/S1473-3099(15)70112-X. Epub 2015 Apr 19.
6
The role of proteases in regulating Eph/ephrin signaling.蛋白酶在调节 Eph/ephrin 信号中的作用。
Cell Adh Migr. 2014;8(4):294-307. doi: 10.4161/19336918.2014.970026.
7
Endothelial barrier dysfunction in septic shock.脓毒性休克中的内皮屏障功能障碍。
J Intern Med. 2015 Mar;277(3):277-293. doi: 10.1111/joim.12331.
8
Parallels between cancer and infectious disease.癌症与传染病之间的相似之处。
N Engl J Med. 2014 Jul 24;371(4):380-3. doi: 10.1056/NEJMcibr1404664.
9
Regulatory mandates for sepsis care--reasons for caution.脓毒症治疗的监管要求——谨慎对待的原因
N Engl J Med. 2014 May 1;370(18):1673-6. doi: 10.1056/NEJMp1400276. Epub 2014 Apr 16.
10
The new normal: immunomodulatory agents against sepsis immune suppression.新常态:抗脓毒症免疫抑制的免疫调节药物
Trends Mol Med. 2014 Apr;20(4):224-33. doi: 10.1016/j.molmed.2014.01.002. Epub 2014 Jan 30.